Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-05-21

Clinical Trial Update: Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics [Phase 3]

View source ↗

Summary

Phase 3 study assessing the efficacy of inhaled albuterol Spiromax in subjects with persistent asthma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Spiromax (albuterol inhalation powder) (albuterol)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2015-05-21